Established markers in second trimester maternal serum. (Q52868608)

9 May 2018

review article

1 reference

title

Established markers in second trimester maternal serum. (English)

1 reference

9 May 2018

author name string

Cuckle H

series ordinal

1

1 reference

9 May 2018

publication date

1 December 1996

1 reference

9 May 2018

published in

Early Human Development

1 reference

9 May 2018

volume

47 Suppl

1 reference

9 May 2018

page(s)

S27-9

1 reference

9 May 2018

Improved parameters for risk estimation in Down's syndrome screening.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Screening for fetal Down syndrome with maternal serum hCG and oestriol: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Prenatal screening for Down's syndrome with use of maternal serum markers

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Antenatal maternal serum screening for Down's syndrome: results of a demonstration project

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Evaluation of multiple-marker screening for Down syndrome in a statewide population

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional programme.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Screening for Down's syndrome: the first two years experience in Bristol

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

Maternal serum free beta hCG screening: results of studies including 480 cases of Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

A prenatal trisomy 21 screening program using alpha-fetoprotein, human chorionic gonadotropin, and free estriol assays on maternal dried blood

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

The advantages of using triple-marker screening for chromosomal abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2896%2901814-2

7 January 2021

10.1016/S0378-3782(96)01814-2

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

9031835

1 reference

9 May 2018